Brought to you by 
CeNeS acquires Cambridge NeuroScience for $2.25/share
09 Aug 2000
Executive Summary
In a stock swap, central nervous system therapeutics developer CeNeS Pharmaceuticals PLC will acquire neuroscience drug discovery firm Cambridge NeuroScience paying in CeNes stock $40.8mm or $2.25 for each Cambridge share, representing a (pr)44% premium. Based on the value of CeNeS stock at the agreement's closing, the transaction price could be as high as $44mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com